Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.32 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
| ▸ | NOS2 | P35228 | 1/20 | 0.32 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.30 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.30 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.30 |
| ▸ | PIP5K1C | O60331 | 1/20 | 0.30 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.30 |
| ▸ | PI4KA | P42356 | 1/20 | 0.30 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.30 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16909250 | 0.81 | NOS3 (0.39) | NOS3NOS1NOS2PIK3CDPIP5K1C | |
| SCHEMBL18594441 | 0.79 | NOS3 (0.40) | NOS3NOS1NOS2PIK3CDPIP5K1C | |
| SCHEMBL14242833 | 0.76 | NOS3 (0.53) | NOS3NOS1NOS2NR1H2NR1H3 | |
| SCHEMBL14242832 | 0.74 | NOS3 (0.35) | NOS3NOS1NOS2NR1H2NR1H3 | |
| SCHEMBL12549572 | 0.73 | PIK3CD (0.31) | NOS3NOS1NOS2PIK3CDPIP5K1C | |
| SCHEMBL16909314 | 0.73 | HTT (0.39) | — | |
| SCHEMBL16651152 | 0.72 | FYN (0.32) | PIK3CDPIP5K1CPIK3CBPI4KAPIK3CG | |
| SCHEMBL1459825 | 0.71 | NOS3 (0.34) | NOS3NOS1NOS2 | |
| SCHEMBL503118 | 0.71 | NOS3 (0.57) | NOS3NOS1NOS2PIK3CB | |
| SCHEMBL19260832 | 0.67 | CA12 (0.36) | PIK3CDPIP5K1CPIK3CBPI4KAPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190152922-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2019-05-23 | — | — | US | disclosed |
| US-20190152922-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2019-05-23 | — | — | US | disclosed |
| US-10179771-B2 | Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | GALAPAGOS NV (BE) | 2019-01-15 | — | — | US | disclosed |
| US-10179771-B2 | Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | GALAPAGOS NV (BE) | 2019-01-15 | — | — | US | disclosed |
| EP-3395802-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | Galapagos N.V. (BE) | 2018-10-31 | — | — | EP | disclosed |
| EP-3097083-B1 | BENZIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2018-08-08 | — | — | EP | disclosed |
| EP-3097083-B1 | BENZIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2018-08-08 | — | — | EP | disclosed |
| US-20170057928-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GILEAD SCIENCES, INC. | 2017-03-02 | — | — | US | disclosed |
| US-20170057928-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GILEAD SCIENCES, INC. | 2017-03-02 | — | — | US | disclosed |
| US-20170057928-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GILEAD SCIENCES, INC. | 2017-03-02 | — | — | US | disclosed |
| EP-3097083-A1 | BENZIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | Galapagos NV (BE) | 2016-11-30 | — | — | EP | disclosed |
| US-9440929-B2 | Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | GALAPAGOS NV (BE) | 2016-09-13 | — | — | US | disclosed |
| US-9440929-B2 | Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | GALAPAGOS NV (BE) | 2016-09-13 | — | — | US | disclosed |
| US-9440929-B2 | Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | GALAPAGOS NV (BE) | 2016-09-13 | — | — | US | disclosed |
| WO-2015110378-A1 | BENZIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2015-07-30 | — | — | WO | disclosed |
| WO-2015110378-A1 | BENZIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2015-07-30 | — | — | WO | disclosed |
| US-20150203455-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GILEAD SCIENCES, INC. | 2015-07-23 | — | — | US | disclosed |
| US-20150203455-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GILEAD SCIENCES, INC. | 2015-07-23 | — | — | US | disclosed |
| US-20150203455-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GILEAD SCIENCES, INC. | 2015-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190152922-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | JAK1, IL6, JAK3 | NOS3 332/4885NOS1 294/4885NOS2 435/4885 |
| US-10179771-B2 | Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | JAK1, JAK3, IL6 | NOS3 364/4885NOS1 334/4885NOS2 473/4885 |
| US-20170057928-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | JAK1, IL6, JAK3 | NOS3 332/4885NOS1 294/4885NOS2 435/4885 |
| US-20150203455-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | JAK1, IL6, JAK3 | NOS3 332/4885NOS1 294/4885NOS2 435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.